New, Unique COVID-19 Antibody Test Gives More Detailed Information on How Immune System Reacts To SARS-CoV-2
By LabMedica International staff writers Posted on 30 Dec 2020 |
Image: Attana Cell 250 instrument (Photo courtesy of Attana)
A new type of rapid antibody test is being developed by researchers that can give more detailed information as compared to the binary antibody tests used today on how the human immune systems react to COVID-19 and other types of viruses and bacteria.
The research groups at Linnaeus University (Växjö, Sweden) and Attana (Stockholm, Sweden) are currently developing and evaluating a new diagnostic platform with the name AVA (Attana Virus Analytics). Tests have been conducted through serum, plasma, and full blood analyses to study individuals’ immune response to SARS Cov-2 and the bacteria Clostridium tetani, which causes tetanus. The samples have been collected from both the bend of the arm and from finger sticks with promising results, which enables easy sampling where results can be ready in 15 minutes.
AVA gives a more nuanced picture of how our immune systems react to different types of viruses and bacteria than the binary tests that are used today. A unique thing about AVA is that the diagnostics platform not only ensures that an antibody test is correct, it can also offer insights concerning the sustainability of immunity. By collecting data on the quantity and quality of antibodies in a sample and then comparing these with samples taken at a later time, an immunity development profile can be established. AVA also offers laboratories the opportunity to validate already existing test results with great accuracy. The platform can assist decision makers concerning, for instance, recommendations, restrictions, and vaccination. Better tests for antibodies will impact at all levels, from individual to authorities as well as for companies and society at large.
“Thanks to this new platform, we obtain a detailed picture of what antibodies are present and how strongly they interact with COVID-19. This should, among other things, help decide who needs to take vaccine and how well an individual has responded to a vaccine,” said Ian Nicholls, professor of chemistry at Linnaeus University.
“Our vision is a general diagnostics platform that is relevant not just at present, during the ongoing pandemic, but one that will also serve a greater broader purpose in the future,” said Teodor Aastrup, CEO at Attana.
Related Links:
Linnaeus University
Attana
The research groups at Linnaeus University (Växjö, Sweden) and Attana (Stockholm, Sweden) are currently developing and evaluating a new diagnostic platform with the name AVA (Attana Virus Analytics). Tests have been conducted through serum, plasma, and full blood analyses to study individuals’ immune response to SARS Cov-2 and the bacteria Clostridium tetani, which causes tetanus. The samples have been collected from both the bend of the arm and from finger sticks with promising results, which enables easy sampling where results can be ready in 15 minutes.
AVA gives a more nuanced picture of how our immune systems react to different types of viruses and bacteria than the binary tests that are used today. A unique thing about AVA is that the diagnostics platform not only ensures that an antibody test is correct, it can also offer insights concerning the sustainability of immunity. By collecting data on the quantity and quality of antibodies in a sample and then comparing these with samples taken at a later time, an immunity development profile can be established. AVA also offers laboratories the opportunity to validate already existing test results with great accuracy. The platform can assist decision makers concerning, for instance, recommendations, restrictions, and vaccination. Better tests for antibodies will impact at all levels, from individual to authorities as well as for companies and society at large.
“Thanks to this new platform, we obtain a detailed picture of what antibodies are present and how strongly they interact with COVID-19. This should, among other things, help decide who needs to take vaccine and how well an individual has responded to a vaccine,” said Ian Nicholls, professor of chemistry at Linnaeus University.
“Our vision is a general diagnostics platform that is relevant not just at present, during the ongoing pandemic, but one that will also serve a greater broader purpose in the future,” said Teodor Aastrup, CEO at Attana.
Related Links:
Linnaeus University
Attana
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants